There is increasing concern about the development of pancreatitis in patients with diabetes mellitus who received longterm glucagon-like peptide-1 (GLP-1) analog treatment. Its pathogenesis is unknown. The effects of GLP-1 agonists on pancreatic endocrine cells are well studied; however, there is little information on effects on other pancreatic tissues that might be involved in inflammatory processes. Pancreatic stellate cells (PSCs) can have an important role in pancreatitis, secreting various inflammatory cytokines/chemokines, as well as collagen. In this study, we investigated GLP-1R occurrence in normal pancreas, acute pancreatitis (AP)/chronic pancreatitis (CP), and the effects of GLP-1 analog on normal PSCs, their ability to stimulate inflammatory mediator secretion or proliferation. GLP-1 receptor (GLP-1R) expression/localization in normal pancreas and pancreatitis (AP/CP) tissues were evaluated with histological/immunohistochemical analysis. PSCs were isolated from male Wistar rats. GLP-1R expression and effects of GLP-1 analog on activated PSCs was examined with real-time PCR, MTS assays and western blotting. In normal pancreas, pancreatic b cells expressed GLP-1R, with only low expression in acinar cells, whereas in AP or CP, acinar cells, ductal cells and activated PSCs expressed GLP-1R. With activation of normal PSCs, GLP-1R is markedly increased, as is multiple other incretin-related receptors. The GLP-1 analog, liraglutide, did not induce inflammatory genes expression in activated PSCs, but induced proliferation. Liraglutide activated multiple signaling cascades in PSCs, and the extracellular signal-regulated kinase pathway mediated the PSCs proliferation. GLP-1Rs are expressed in normal pancreas and there is marked enhanced expression in AP/CP. GLP-1-agonist induced cell proliferation of activated PSCs without increasing release of inflammatory mediators. These results suggest chronic treatment with GLP-1R agonists could lead to proliferation/chronic activation of PSCs, which may lead to important effects in the pancreas.
chemokines, [29] [30] [31] which can participate in inflammatory processes, they can also proliferate and secrete collagen. 32, 33 Although numerous stimulants can affect PSCs including activation of some G-protein-coupled receptors (PGE2, angiotensin, CCK-A, CCK-B), [34] [35] [36] [37] [38] [39] it is unknown if GLP-1R occurs on PSC either in normal pancreas or pancreatic disease states or, whether PSCs are activated in AP or CP, or if it does occur, whether the GLP-1R agonists affect the PSC signaling cascade, growth or ability to release inflammatory mediators. To address these questions, in this study we have examined the occurrence of the GLP-1R in PSCs in normal pancreas, in AP/CP models, as well as the ability of the GLP-1R agonist, liraglutide, to alter function of PSCs and effect PSCs behavior.
MATERIALS AND METHODS Materials
Liraglutide was from Shoyaku (Fukuoka, Japan), U0126 and cerulein from Sigma-Aldrich (St Louis, MO, USA), Recombinant rat PDGF-BB from R&D Systems (Minneapolis, MN, USA) and rabbit anti-phosphorylated extracellular signalregulated kinase (ERK) antibody, rabbit anti-phosphorylated JNK antibody, rabbit anti-phosphorylated p38 antibody, rabbit anti-phosphorylated Akt antibody, mouse anti-total IkB antibody anti-rabbit IgG-HRP-conjugated antibody and antimouse IgG-HRP-conjugated antibody from Cell Signaling Technology (Beverly, MA, USA). Rabbit anti-GLP-1R antibody, mouse anti-glial fibrillary acidic protein (GFAP) and mouse anti-alpha smooth muscle actin (a-SMA) were from Abcam PLC (Cambridge, UK), Goat anti-type I collagen antibody from Southern Biotechnology (Birmingham, AL, USA), rabbit antibody against glyceraldehydes-3-phosphate dehydrogenase (GAPDH) from Trevigen (Gaithersburg, MD, USA) and anti-rabbit IgG Alexa488-conjugated antibody, anti-mouse-IgG-Alexa555-conjugated antibody, anti-goat-IgGAlexa350-conjugated antibody and Hoechst33342 were from Invitrogen (Carlsbad, CA, USA).
Animals
Fifteen-week-old male Wistar rats and Wistar/Bonn-Kobori (KOB) rats (KBT Oriental, Saga, Japan) were used. All animal procedures were performed in accordance with the guidelines of the Committee on Animal Care (Kyushu University). L-arginine-induced AP was performed by administrating a single intraperitoneal injection of 4.0 g/kg body weight L-arginine monohydrochloride in 0.9% sodium chloride (pH7.0) as described previously. 40 Rats were fed ad libitum after the treatment and killed 72 h later. Cerulein-induced AP was also performed by injecting intraperitoneally into the right lower quadrant with a 50 mg/kg/body weight of cerulein dissolved in 0.9% saline in a volume of 100 ml. Injections were at hourly intervals up to seven injections. Animals were killed 8 h after the first injection of cerulein. To study results in CP, a male Wistar/Bonn-KOB rats 41, 42 were used as previously described. 31 Isolation of PSCs and Cell Culture PSCs were isolated from the pancreas of male Wistar rats and were maintained as previously described. 43 Cell purity was assessed initially by a typical star-like configuration and by detecting vitamin A autofluorescence and was 495%. To further assess the purity, in the third passage (activated PSCs) using immunohistochemistry to assess the co-expression of a-SMA (marker of activated stellate cells) and the presence of a cell (Hoechst33342) using ImageJ (NIH). We found the purity of PSCs was 499%. Furthermore, trypsin mRNA expression as a marker for acinar cell contamination was assessed using PCR (primers: Table 1 , PCR conditions: Tm ¼ 60 1C, cycles 40). In the third passage of PSCs and was 41 million times lower than in acinar cells, indicating contamination by acinar cells was negligible. Unless otherwise specified, PSCs were incubated in serum-free medium for 24 h before the addition of experimental reagents. The ERK-specific inhibitor (U0126) was added 30 min before the addition of liraglutide.
Expressional Changes of Incretin-Related and Pancreatitis-Related mRNAs in PSCs: Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Total RNA was extracted from PSCs using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) as previously described. 44 Total RNA was reverse transcribed into first-strand complementary DNA and RT-PCR was performed using a LightCycler Real-Time PCR system (Roche, Switzerland) as previously described. 44 To control for variations in the reactions, all PCR data were normalized against GAPDH expression. The PCR products were separated in a 2% agarose gel and visualized under UV illumination. Sequences of primers were listed on Table 1 .
Histochemical Analysis
Specimens from the body of each pancreas were used for histopathological analysis. The pancreas specimens were fixed in 4% paraformaldehyde in PBS and embedded in paraffin. Tissue sections were stained with hematoxylin/eosin (HE) or Masson-Trichrome (MT), which preferentially labels collagen fibrils.
Immunofluorescent Staining
Immunofluorescent staining was performed as previously described. 43 Briefly, double-immunofluorescent staining for GLP-1R and GFAP (staining quiescent PSCs), type I collagen/ a-SMA (staining activated PSCs) was performed as previously described. 31 Hoechst33342 was used for nuclear counter staining. The degree of colocalization of GLP-1R and a-SMA was calculated using ImageJ (NIH).
Western Blotting
Western blot analysis was performed as previously described. 43 Briefly, cells were lysed in RIPA buffer and cellular GLP-1R in PSCs T Nakamura et al proteins were fractionated by electrophoresis on a polyacrylamide gel (Bio-Rad, Hercules, CA, USA). The proteins were transferred onto a nitrocellulose membrane (Bio-Rad), and it was incubated for 2-6 h with primary antibodies (at 1 : 1000-10 000 dilutions). After incubating with HRPconjugated secondary antibody (at 1 : 10 000 dilution), the proteins were visualized by using an ECL kit and ImageQuant LAS 4000mini (GE Healthcare). Levels of phosphorylated ERK, JNK, p38, Akt, total IkB and GAPDH were determined by General-Purpose Analysis Software Multi Gauge.
Cell Proliferation Assay: MTS Assay
Cell proliferation was assessed by the MTS assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Madison, WI, USA) as previously described. 44 
Statistical Analysis
Results are expressed as the means (s.e.m.) of 3-4 separate cell preparations. The two-tailed unpaired Student's t-test was used for the statistical analyses. P-values of o0.05 were considered statistically significant.
RESULTS

Expression of the GLP-1R in Normal Pancreas
Initially, we performed immunofluorescent staining to evaluate the expression of the GLP-1R in normal pancreas from male Wistar rats (Figures 1 and 2) . As previously reported, 45 high expression of the GLP-1R occurred in pancreatic islets ( Figure 1a) . a-SMA-positive capillary vessel cells in the islets did not show GLP-1R stain (Figures 1b and d) . Only weak staining for GLP-1R was seen in acinar cells. In the normal pancreas specimen, no a-SMA-positive PSCs (activated myofibroblast-like cells) were seen, however, GFAP-positive quiescent PSCs showed low expression of the GLP-1R (Figures 1 e-g ). To investigate further expression of GLP-1R in normal islets, the GLP-1R distribution was examined in b cells (central islet area) and a cells (islet-periphery for GLP-1R; Figures 2a-f ). GLP-1R was only present in b cells, a finding similar to some reports, 45, 46 however, different from others, which reported the GLP-1R also in a cells. [47] [48] [49] Rat GLP-2R
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Gene Sequence
Rat trypsin We also performed the reverse analysis by determining the percentage of GLP-1R-positive cells that were activated PSCs, and which was 71% in CP models (Figure 5a ). These data support the conclusion that GLP-1R expression in these inflammatory conditions (AP/CP), can also occur in non-stellate cells (acinar cells, islet cells and inflammatory cells). The proportion of GLP-1R occurring in non-stellate cells is higher when the inflammation is mild (76% AP, Figure 3a ; 29% CP, Figure 5 ). DCs also expressed GLP-1R (Figures 5a and d) .
Both Quiescent and Activated PSCs from Normal Rat Expressed the GLP-1R In Vitro and the Expression is Increased in Activated PSCs
To further investigate the expression of GLP-1R in normal pancreas and the result of its activation, we studied PSCs isolated from normal pancreas in both a quiescent phase (first passage: 1 day; Figure 6a ) and an activated phase (third passage) in vitro (Figure 6b ). Activation of the PSCs during the third passage was confirmed by demonstrating the presence of immunofluorescent staining for a-SMA (Supplementary Figure S1) . GLP-1R expression by immunohistochemical staining suggested that there was a marked increase in the expression in the PSCs, with activation (compare Figures 6a vs 6b) . We confirmed that all of the PSCs in both quiescent and activated state expressed GLP-1R with nuclear staining (Supplementary Figure S1) . Not only GLP-1R, but also other incretin-related mRNAs (GLP-2R, GIPR, GlucagonR, proglucagon, GIP and DPPIV) were expressed in PSCs in sequential 1-4 passages (Figure 6c ). Quantitative real-time PCR revealed greater expression of GLP-1R, GLP-2R and GIP-R mRNA in activated PSCs from the third passage (activated) compared with quiescent PSCs from the first passage (quiescent) (Figure 6d ). GLP-1R in PSCs T Nakamura et al chemokines (MCP-1, CINC-1 and CX3CL1; Figure 7a ). a-SMA and type I collagen mRNA, which are cell activation markers, were also not increased by liraglutide (Figure 7a ). However, liraglutide stimulated PSCs proliferation at 24 and 48 h after its addition (Figure 7b ).
The GLP-1 Agonist, Liraglutide, Activated Various Cell Signaling Cascades in PSCs Phosphorylation of MAPKs (ERK, JNK and p38) and Akt was rapidly stimulated by liraglutide (by 5 min) with a maximal response between 5 and 15 min (lanes 2 and 3; Figure 7c ). Degradation of total IkB also occurred rapidly with liraglutide treatment indicating NF-kB activation.
PDGF-BB was used as a positive control and activated each of the cell signaling pathways (lane 6).
ERK Activation Has an Essential Role in
Liraglutide-Induced Cell Proliferation of PSCs ERK activation in PSCs is important in stimulating the growth effects of numerous stimuli. 43, 50 To assess this, U0126, an ERK inhibitor, at the indicated concentrations (1-10 mM) was added 30 min before liraglutide (10 mM). Liraglutide-induced cell proliferation was completely abolished by U0126, demonstrating ERK activation is important in mediating liraglutide-induced proliferation of PSCs (Figure 7d ).
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GLP-1R in PSCs
T Nakamura et al DISCUSSION GLP-1 analogs and DPPIV inhibitors are now one of the main drugs used for treatment in patients with diabetes mellitus. [1] [2] [3] The use of these drugs has generally been associated with few side-effects, however, a concern receiving increasing attention is the possible development of pancreatitis. 7, 8 A number of studies report an association of GLP-1-agonist use and pancreatitis, [10] [11] [12] [13] [14] [15] We first examined GLP-1R expression in normal pancreas, followed by its expression in PSCs in the pancreas of various pancreatitis models (AP/CP). Our results show GLP-1R is present predominantly in islets of normal tissue, although it is also weakly present in acinar cells. In the normal islets, we found it present in b cells, not a cells, which is consistent with findings in some studies, 45, 54 but differ from others. 47 GLP-1R has been identified by various methods on islets of numerous species (rat, human and hamsters) [55] [56] [57] and GLP-1R activation has also been shown to alter islet cell function (insulin release). 56 Hörsch et al. 45 reported that the GLP-1R had a high density in the b-cell zone and were not detected in the a-cell zone, similar to our results. This distribution pattern is in accordance with the numerous studies reporting GLP-1-binding sites on b-cell lines. 58, 59 In contrast, the possibility of GLP-1R expression in a cells is controversial, with some reporting it is present, 47, 48 whereas others report no GLP-1R in a cells, similar to our results. 45, 54 Our findings that normal pancreatic acinar cells have a low level of expression of GLP-1R is similar to those from some reports 60,61 but differ from others, which report no GLP-1R in normal pancreatic acinar cells by assessing GLP-1R mRNA levels. 45, 57 Furthermore, the pancreatic acinar cell line, AR42J cells responds to GLP-1R agonist (increased cAMP) 60 raising the possibility that acinar cells might potentially contribute to liraglutide-induced pancreatitis. Further investigation focusing on acinar cell responses to liraglutide treatment would be required in the future. We did not find GLP-1R on DCs in normal pancreas. This result is similar to the findings in two other studies. 45, 57 Finally, in normal pancreas, we did not find GLP-1R in normal pancreatic arteries. This result is consistent with another study. 62 A number of our results, in both AP and CP models, are consistent with the conclusion that GLP-1Rs are expressed in activated PSCs and expression is increased over normal pancreas. First, we observed an increased number of activated PSCs in L-arginine-induced AP, which is consistent with findings from a previous report, 63, 64 which demonstrated increased a-SMA expression (a marker for activated PSCs) coincided with TGF-b1 activation in this model. Second, in the CP model (WBN/KOB-rat), we found increased numbers of PSCs, which is consistent with findings in other studies. 65, 66 Third, we found in both the pancreatitis models a marked overexpression of GLP-1R, which generally colocalized with activated PSCs or with areas of marked increased in PSC activity in the CP model with enhanced fibrosis. However, in our study, the localization of PSCs (peri-acinar and peri-islet) in pancreatitis differed in some aspects from other reports. In some studies, activated PSCs are reported in vascular walls, 37,66 whereas we could not find this. We did, however, find that dilated vascular structures in our AP model 
T Nakamura et al stained positive for a-SMA. We found activated PSCs not only in peri-acinar lesions, but also in peri-islet lesions in the CP model that differs from that reported in another pancreatitis study, which showed only a peri-acinar location of PSCs. 65, 66 In quiescent PSCs, we found the expression of GLP-1R, as well as numerous other incretin-related receptors including the receptors for glucagon, gastric inhibitory peptide (GIP) receptor and GLP-2R. This result is similar to others in pancreatic b cells, which are reported to express glucagon receptors and GIP receptors as well as GLP-1R, whereas a cells express glucagon and GIP receptors, but no GLP-1Rs. 54 In culture-activated PSCs from normal pancreas, our results show there is a marked increase in the expression of GLP-1R 69 and in fact, it attenuated the increases in both ROS and PTX3 induced by TNF-a, suggesting it was not increasing inflammatory activity. Exendin-4, a GLP-1R agonist, also suppressed basal expression of several inflammatory mediators and in combination with phosphodiesterase inhibitors, decreased CXCL10 expression by IFN-g (a type II-interferon) in human islets and in MIN6 cells (a mouse b-cell line). 70 Finally, GLP-1 attenuated IL-1b-mRNA expression induced by lipopolysaccharide (a component of Gram-negative bacteria) in rat astrocytes. 71 These results are consistent with the conclusion that in PSCs and other cells with GLP-1Rs, GLP-1R agonists do not stimulate inflammatory responses, and may, in fact, attenuate their development by other inflammatory stimulants. From our data, we cannot establish whether the prolonged GLP-1R agonist treatment affects quiescent PSCs and induces them to proliferate and stay activated. Therefore, at present we cannot address the events of induction of the pancreatitis.
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GLP-1 has not only insulinotropic effects in b cells, but also has cell-proliferative and anti-apoptotic effects. 72, 73 A proliferative effect by GLP-1 agonists has also been reported in mouse skin cells and the pancreatic acinar cell line, AR42J. 74, 75 Our results show that the GLP-1R agonist, liraglutide, stimulated proliferation of PSCs. These results are similar to the effects of activation of two other GPCRs on PSCs, the AT1R and PAR2-R, which also result in PSC cell proliferation. 35, 36, 68 In contrast, our results differ from activation of ET-1 receptors on PSCs, which does not stimulate proliferation. 67, 76 The role of the proliferative effect on PSCs of liraglutide and the other GPCRs in AP or CP at present is unknown, as is the possibility that prolonged treatment with GLP-1R agonists for diabetes or other diseases, may lead to increased fibrosis due to enhanced PSC growth and activation.
In other cells, various signaling cascades, including activation of MAPK, phospho-inositol-3-phosphate kinase (PI3K), adenylate cyclase and PKCz by GLP-1 agonists, mediate the effects of GLP-1R activation on various cellular functions including insulin secretion and biosynthesis, b-cell proliferation and neogenesis. 16, 77, 78 We found several signaling cascades are activated by liraglutide in PSCs including ERK, JNK, p38, Akt and IkBa. Furthermore, the ERK activation was essential for GLP-1R-mediated PSC proliferation. These results have similarities and differences from GLP-1R-mediated growth reported in other cells. GLP-1-induced cell proliferation of b cells is inhibited by a ERK inhibitor, suggesting the involvement of ERK. 73 Furthermore, ERK activation by GLP-1 in mouse skin cells 74 mediates its proliferative effect. In contrast, in other studies, 72, 73 protein kinase A, PI3K and PKC-zeta activation are needed for GLP-1-induced cell proliferation of b cells. Our finding of high basal ERK level and a rapid increase in ERK activation with liraglutide that return to normal by 30 min is similar to reports by others in PSCs with other stimuli and in other cells with ERK activation. 79, 80 Our results with GLP-1R-mediated PSC proliferation also have similarities and differences with the ability of other GPCRs to stimulate growth in PSCs. Similar to our findings, PSC cell proliferation induced by activation of ERK signaling pathway is needed for growth mediated by PAR2-receptor or angiotensin-receptor activation, however, the latter effect requires EGFR transactivation. 35, 68 These results show that ERK is one of the important signal cascades mediating cell proliferation of PSCs.
In conclusion, we demonstrated the GLP-1R expression in normal pancreas occurs primarily in b cells and only weakly in acinar cells or quiescent PSCs. However, in AP/CP there is marked increase in GLP-1R, primarily in PSCs. Furthermore, with activation of normal PSCs, there is marked increase in the GLP-1R level. However, in activated PSCs, liraglutide, a GLP-1R agonist, did not stimulate release of inflammatory cytokines/chemokines, however, it stimulated PSC proliferation, which was dependent on ERK activation. Chronic GLP-1 use in humans has recently been reported to cause expansion of both exocrine and endocrine pancreas and led to concerns about its unattended proliferative effects in these pancreatic tissues. 81 Our study GLP-1R in PSCs T Nakamura et al raises a similar concern for its long-term proliferative effect on PSCs. At present, it remains unclear whether these changes in PSCs contribute to the development of pancreatitis seen in patients with chronic use of GLP-1R agonists, or whether they could lead to complications of the increased PSCs proliferation due to long-term use of GLP-1 agonists.
